Vaishnav Smruti, Pandya Dharak, Shrivastava Rama, Patel Nimeshkumar, Phatak Ajay G, Patel Alpaben
Obstetrics and Gynaecology Department, Pramukhswami Medical College and Shree Krishna Hospital, Bhaikaka University, Karamsad, Anand, Gujarat, India.
Consultant Physician, Yogeshwar Hospital, Chhotaudepur, Gujarat, India.
J Family Med Prim Care. 2023 Dec;12(12):3393-3398. doi: 10.4103/jfmpc.jfmpc_1185_23. Epub 2023 Nov 22.
Associations between adverse maternal complications and fetal outcomes are known entity in thyroid disorders during pregnancy. Thus, prompt identification of thyroid disorders and timely initiation of treatment is essential. Universal screening and early treatment of pregnant women for thyroid disorder should be considered especially in a resource-limited country like India with a high prevalence of undiagnosed thyroid disorders and adverse feto-maternal outcomes.
Early treatment will prevent feto-maternal complications in thyroid disorders in pregnant females visiting outpatient department in tertiary care hospital in rural settings.
This study was conducted in a tertiary care rural-based medical college with participation from departments of Obstetrics and Gynaecology, Medicine, and ENT.
Expectant mothers in first trimester who had urine pregnancy test positive in outpatient clinic were included after a written informed consent. Detailed history and examination was done. TSH was done if abnormal-FT3 and FT4 were done. All thyroid disorders were treated according to American Thyroid Association (ATA) 2017 guideline. All pregnancies were followed up for maternal complications and fetal outcomes.
Data from the performa were entered in Office Excel and analysis was performed using STATA (14.2). Descriptive statistics (mean [standard deviation], Frequency [%], etc.) were used to depict profile of study participants, prevalence of thyroid dysfunction, and outcome measures. Chi-square test was employed to assess the association between thyroid dysfunction and various maternal and fetal outcomes. A value less than. 05 was considered statistically significant.
Of 350 pregnant females, 83 (23.5%) pregnant females had thyroid disorder. Of which, 33 (9.4%) had subclinical hypothyroidism, 37 (10.5%) had overt hypothyroidism, 11 (3.1%) had subclinical hyperthyroidism, and two (0.5%) had hyperthyroidism. The prevalence of hypothyroidism in pregnancy increases with increasing age ( value. 001) and not associated with parity, abortion, and consumption of iodized salt. Total patients with feto-maternal outcome follow-up were 241. Pre-eclampsia ( value. 004) was a significant complication in hypothyroid mothers. There was no significant difference in the rate of cesarean section and preterm delivery in hypothyroid and euthyroid mothers. Neonatal outcomes showed more trends of abortion, fetal demise, and IUFD in the hypothyroid group, although not statistically significant. ( value. 07).
Due to the high prevalence of thyroid disorders during pregnancy, universal screening of thyroid disorders should be done in early pregnancy instead of high-risk screening. Early detection and early treatment in the first 10 weeks of pregnancy help to prevent maternal and fetal complications of thyroid disorders in pregnancy. Pre-eclampsia is to be monitored in treated pregnant females with hypothyroidism.
孕期甲状腺疾病中,不良母体并发症与胎儿结局之间的关联是已知的。因此,及时识别甲状腺疾病并及时开始治疗至关重要。尤其是在像印度这样资源有限的国家,未诊断出的甲状腺疾病和不良母婴结局患病率很高,应考虑对孕妇进行甲状腺疾病的普遍筛查和早期治疗。
早期治疗将预防在农村地区三级护理医院门诊就诊的怀孕女性甲状腺疾病中的母婴并发症。
本研究在一所农村三级护理医学院进行,妇产科、内科和耳鼻喉科参与其中。
在门诊尿妊娠试验呈阳性的孕早期准妈妈在签署书面知情同意书后被纳入。进行了详细的病史询问和检查。若促甲状腺激素(TSH)异常则检测游离三碘甲状腺原氨酸(FT3)和游离甲状腺素(FT4)。所有甲状腺疾病均根据美国甲状腺协会(ATA)2017年指南进行治疗。对所有妊娠进行随访以观察母体并发症和胎儿结局。
将表格数据录入办公软件Excel,并使用STATA(14.2)进行分析。描述性统计(均值[标准差]、频率[百分比]等)用于描述研究参与者的概况、甲状腺功能障碍的患病率和结局指标。采用卡方检验评估甲状腺功能障碍与各种母婴结局之间的关联。P值小于0.05被认为具有统计学意义。
在350名怀孕女性中,83名(23.5%)怀孕女性患有甲状腺疾病。其中,33名(9 .4%)患有亚临床甲状腺功能减退,37名(10.5%)患有显性甲状腺功能减退,11名(3.1%)患有亚临床甲状腺功能亢进,2名(0.5%)患有甲状腺功能亢进。孕期甲状腺功能减退的患病率随年龄增加而升高(P值0.001),与产次、流产和碘盐摄入无关。进行母婴结局随访的患者总数为241名。子痫前期(P值0.004)是甲状腺功能减退母亲的一项显著并发症。甲状腺功能减退和甲状腺功能正常的母亲在剖宫产率和早产率方面无显著差异。新生儿结局显示,甲状腺功能减退组的流产、胎儿死亡和死产趋势更多,尽管无统计学意义(P值0.07)。
由于孕期甲状腺疾病患病率高,应在孕早期进行甲状腺疾病的普遍筛查而非高危筛查。妊娠前10周的早期发现和早期治疗有助于预防孕期甲状腺疾病的母婴并发症。对接受治疗的甲状腺功能减退孕妇应监测子痫前期。